DB
MIST icon

Dmitry Balyasny’s Milestone Pharmaceuticals MIST Stock Holding History

Dmitry Balyasny’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$295K Sell
220,498
-630,827
-74% -$1.01M ﹤0.01% 2711
2026
Q1 		$1.01M Buy
+851,325
New +$1.49M ﹤0.01% 2070

Other funds holding MIST

PCM
Pavaki Capital Management Pueblo, Colorado $287M AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Dmitry Balyasny's MIST Position: Q2 2026 in Review

Dmitry Balyasny reduced its Milestone Pharmaceuticals (MIST) stake by 74% in Q2 2026, selling an estimated $1.01M and leaving 220,498 shares worth $295K. The position accounts for ﹤0.01% of the portfolio, ranked #2711.

Dmitry Balyasny first reported a position in MIST in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.01M in Q1 2026. 78 funds tracked by Wall St. Rank hold MIST as of Q2 2026.

  • Dmitry Balyasny held 220,498 shares of Milestone Pharmaceuticals worth $295K as of Q2 2026.
  • Dmitry Balyasny sold 630,827 Milestone Pharmaceuticals shares in Q2 2026, an estimated $1.01M.
  • Milestone Pharmaceuticals made up ﹤0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #2711 holding.
  • Dmitry Balyasny first reported a position in Milestone Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Dmitry Balyasny's Milestone Pharmaceuticals position peaked at $1.01M in Q1 2026.
  • 78 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.